SCHEMBL1542623

SCHEMBL1542623

COc1c(CCc2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C1(C)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.72
DRD3 P35462 1/20 0.37
PDPK1 O15530 1/20 0.35
ADRA1D P25100 1/20 0.33
ADRA1A P35348 1/20 0.33
ADRA1B P35368 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33
PARP1 P09874 1/20 0.33
EP300 Q09472 1/20 0.33
TDP2 O95551 1/20 0.33
ABCB1 P08183 1/20 0.32
PIP4K2A P48426 1/20 0.32
PIP4K2B P78356 1/20 0.32
CDK2 P24941 1/20 0.32
CDK9 P50750 1/20 0.32
IRAK1 P51617 1/20 0.32
PTK2 Q05397 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542570 0.86 CYP3A4 (0.53) CYP3A4
SCHEMBL1542581 0.84 CYP3A4 (1.00) CYP3A4DRD3EP300
SCHEMBL1542708 0.79 CYP3A4 (0.48) CYP3A4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL724765 0.79 CYP3A4 (0.75) CYP3A4PDPK1PIK3CDPIK3CAPIK3CB
SCHEMBL2691615 0.76 CYP3A4 (0.48) CYP3A4PDPK1PIK3CDPIK3CAPIK3CB
SCHEMBL2128400 0.75 CYP3A4 (0.84) CYP3A4PARP1EP300JAK2JAK1
SCHEMBL1542343 0.75 CYP3A4 (0.70) CYP3A4DRD3PDPK1EP300KDM4E
SCHEMBL848054 0.75 CYP3A4 (0.46) CYP3A4PDPK1PIK3CDPIK3CAPIK3CB
SCHEMBL2127123 0.74 CYP3A4 (0.70) CYP3A4PDPK1PIK3CDPIK3CAPIK3CB
SCHEMBL1543041 0.74 CYP3A4 (0.78) CYP3A4PIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP disclosed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885DRD3 1939/4885PDPK1 4145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.